Literature DB >> 12892015

[Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy].

R A de Moor1, L Mourad, J ter Haar, A C Egberts.   

Abstract

Withdrawal symptoms occurred in a male neonate after maternal use of venlafaxine for depression during pregnancy. The symptoms were restlessness, hypertonia, jitteriness, irritability and poor feeding. The diagnosis was confirmed by a temporary improvement after administration of a low dose (1 mg) of venlafaxine to the boy. Eventually the symptoms began to decline spontaneously, and ceased after 8 days. Exposure to venlafaxine and other antidepressants which inhibit serotonin reuptake during the third trimester of pregnancy carries the risk of a neonatal withdrawal syndrome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12892015

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  8 in total

1.  Neonatal seizures on EEG after in utero exposure to venlafaxine.

Authors:  Chris J C Hoppenbrouwers; Jacob Bosma; Hanneke J M B Wennink; Antonius A J Hilgevoord; Marion Heres; Adriaan Honig
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

Review 2.  Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates?

Authors:  Gideon Koren; Doreen Matsui; Adrienne Einarson; David Knoppert; Meir Steiner
Journal:  CMAJ       Date:  2005-05-24       Impact factor: 8.262

3.  Myoclonic seizures in a preterm baby: is this a presentation of venlafaxine withdrawal?

Authors:  Althaf Ansary; Samuel Ibhanesebhor; Chikkanayakanahalli Manjunatha
Journal:  Singapore Med J       Date:  2014-04       Impact factor: 1.858

Review 4.  Antidepressant use in pregnancy: a critical review focused on risks and controversies.

Authors:  N Byatt; K M Deligiannidis; M P Freeman
Journal:  Acta Psychiatr Scand       Date:  2012-12-14       Impact factor: 6.392

Review 5.  Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects.

Authors:  Irma Convertino; Alice Capogrosso Sansone; Alessandra Marino; Maria T Galiulo; Stefania Mantarro; Luca Antonioli; Matteo Fornai; Corrado Blandizzi; Marco Tuccori
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

Review 6.  Serotonin reuptake inhibitor-induced perinatal complications.

Authors:  Salvatore Gentile
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 7.  The safety of newer antidepressants in pregnancy and breastfeeding.

Authors:  Salvatore Gentile
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 8.  Is there a correlation between venlafaxine therapy during pregnancy and a higher incidence of necrotizing enterocolitis?

Authors:  Markus Treichel; Katharina Schwendener Scholl; Ulf Kessler; Alexander Joeris; Mathias Nelle
Journal:  World J Pediatr       Date:  2009-01-27       Impact factor: 2.764

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.